|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
1,250,000,000 |
Market
Cap: |
84.65(B) |
Last
Volume: |
3,579,101 |
Avg
Vol: |
8,731,484 |
52
Week Range: |
$64.58 - $87.29 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 259 |
Guru Rank Value : 4.6 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
12,230 |
25,472 |
38,458 |
80,792 |
Total Sell Value |
$890,904 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
Total People Sold |
1 |
3 |
3 |
4 |
Total Sell Transactions |
3 |
5 |
9 |
14 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dickinson Andrew D |
EVP, Chief Financial Officer |
|
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
769 |
11,756 |
|
- |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2020-03-10 |
4 |
D |
$72.34 |
$37,906 |
D/D |
(524) |
12,199 |
|
- |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,865 |
12,723 |
|
- |
|
Cogan John Francis |
Director |
|
2020-03-09 |
4 |
AS |
$77.97 |
$188,142 |
D/D |
(2,413) |
54,860 |
|
2% |
|
Cogan John Francis |
Director |
|
2020-03-09 |
4 |
OE |
$19.63 |
$47,367 |
D/D |
2,413 |
57,273 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-03-02 |
4 |
AS |
$70.83 |
$740,014 |
D/D |
(10,441) |
14,644 |
|
1% |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2020-03-01 |
4 |
D |
$69.36 |
$1,797,950 |
D/D |
(25,922) |
47,570 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
54,288 |
73,492 |
|
- |
|
Lofton Kevin E |
Director |
|
2020-02-24 |
4 |
OE |
$19.63 |
$426,364 |
D/D |
21,720 |
86,579 |
|
- |
|
Dickinson Andrew D |
EVP, Chief Financial Officer |
|
2020-02-15 |
4 |
A |
$53.67 |
$21,199 |
D/D |
395 |
10,987 |
|
- |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2020-02-15 |
4 |
A |
$53.67 |
$14,169 |
D/D |
264 |
10,858 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-02-15 |
4 |
A |
$53.67 |
$21,199 |
D/D |
395 |
25,085 |
|
- |
|
Wilson Gayle E |
Director |
|
2020-02-10 |
4 |
S |
$67.72 |
$1,470,878 |
D/D |
(21,720) |
126,782 |
|
-12% |
|
Wilson Gayle E |
Director |
|
2020-02-10 |
4 |
OE |
$19.63 |
$426,364 |
D/D |
21,720 |
148,502 |
|
- |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2020-02-10 |
4 |
D |
$68.99 |
$15,109 |
D/D |
(219) |
10,594 |
|
- |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2020-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
779 |
10,813 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-02-10 |
4 |
AS |
$69.32 |
$204,494 |
D/D |
(2,950) |
24,690 |
|
12% |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-02-10 |
4 |
OE |
$24.30 |
$71,670 |
D/D |
2,950 |
27,640 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-02-07 |
4 |
S |
$70.00 |
$99,820 |
D/D |
(1,426) |
24,690 |
|
-8% |
|
Wold Olsen Per |
Director |
|
2020-02-07 |
4 |
S |
$69.00 |
$1,399,458 |
D/D |
(20,282) |
97,854 |
|
-8% |
|
Wold Olsen Per |
Director |
|
2020-02-07 |
4 |
OE |
$20.65 |
$418,722 |
D/D |
20,282 |
118,136 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-02-06 |
4 |
D |
$68.21 |
$88,809 |
D/D |
(1,302) |
26,116 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-02-06 |
4 |
OE |
$0.00 |
$202,800 |
D/D |
7,728 |
27,418 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2020-02-06 |
4 |
S |
$68.18 |
$340,901 |
D/D |
(5,000) |
24,690 |
|
-9% |
|
Wold Olsen Per |
Director |
|
2020-02-06 |
4 |
S |
$68.12 |
$1,479,605 |
D/D |
(21,720) |
97,854 |
|
-9% |
|
2499 Records found
|
|
Page 14 of 100 |
|
|